On Monday, Moderna Inc. (NASDAQ:MRNA) shares edged higher after revealing plans to develop a vaccine for the Omicron variant. The stock surged nearly 10% after it said a new covid vaccine targeting the Omicron variant could be ready by early 2022. Moderna had rocketed more than 21% on Friday amid fears of the potential impact […]
Full ArticleShould you buy Moderna stock as it develops a vaccine for the Omicron variant?
Invezz
0 shares
2 views
You might like
Related news coverage
Omicron Variant May Have Reached Europe Earlier Than Thought
Newsy
Watch VideoEconomic powerhouses Japan and France reported their first cases of the omicron variant Tuesday, while new findings..
Advertisement
More coverage
Dow falls 200 points as vaccine maker warns of diminished effectiveness against Omicron variant
Business Insider
Moderna's CEO told the Financial Times "there is no world" in which vaccine effectiveness is the same against Omicron as against..